Evaluation of Prognostic Factors and Validation of Tumor Response Ratios after Neoadjuvant Chemotherapy in Patients with Breast Cancer

Abstract

Purpose: In the treatment of breast cancer, neoadjuvant chemotherapy (NAC) is useful to reduce breast cancer size before surgical intervention. Patients who achieve a pathologic complete response (pCR) to NAC have improved overall survival (OS). However, the relationship between prognosis and partial response is yet unclear. In this study, we evaluated prognostic factors and the tumor response ratio (TRR) method among patients who received NAC. Methods: Clinicopathologic factors were evaluated to predict OS. The TRR was calculated by dividing pathologic tumor size by clinical tumor size. TRRs were then categorized into four groups, and the survival times for the different TRR groups were compared using statistical evaluation. Results: Clinical N stage (p= 0.02), overall stage (p= 0.04), pathologic N stage (p= 0.03), hormone receptor status (p= 0.01), and lymphovascular invasion (p= 0.02) were significantly associated with OS. Pathologic overall stage and TRR did not correlate with OS. Patients with a pCR exhibited the best survival rates using the current staging system and the TRR method. Conclusion: Clinicopathologic factors can be easily applied to predict OS, and clinicians could use these parameters until an accurate, simple, and highly discriminatory methods is developed to assess breast cancer patients with a partial.

Prognostic Factors in Patients with Locally Advanced Breast Cancer Treated by Neoadjuvant Chemotherapy

“…Rates of pathologic complete response (pCR) range from 16% to 20% according to the histologic subtypes of tumor and treatment modalities. Achievement of pCR has been correlated with better disease-free survival (DFS) and overall survival (OS) [6][7][8]. staining was scored as 0, 1+, 2+, or 3+.…”